Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Research on the links between tenofovir and other antiretrovirals, SARS-CoV-2 infection and COVID severity has produced mixed results.
People starting on integrase inhibitors were no more likely to have heart attacks, strokes or cardiovascular procedures.
However, all integrase inhibitors were associated with similar weight gain.
Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.
The FDA has granted a breakthrough designation to Bristol-Myers Squibb’s investigational HIV attachment inhibitor BMS-663068.
Harvoni and the combination of Sovaldi and daclatasvir were the least likely to cause a severe reaction with the HIV regimens of a cohort of H...
A revision of U.S. HIV treatment guidelines has removed Atripla (efavirenz/tenofovir/emtricitabine) from the priority list of first-line antir...
Researchers presented results from various studies on hepatitis C treatment and care at a medical conference in Seattle.
People who coinfected with HIV and hepatitis C looking to take the HCV drug Olysio may need to change HIV medications to avoid drug-drug...
Harvoni yielded a 96 percent cure rate among people with genotype 1 of hepatitis C, as well as a small number of those with genotype 4.
Given to treatment-experienced people with HIV, the attachment inhibitor BMS-663068 (fostemsavir) demonstrated potentcy in the range of...
Twelve weeks of Gilead Sciences’ newly approved Harvoni cured nearly all people with genotype 1 of hepatitis C who were coinfected with HIV in...
A trio of Sustiva (efavirenz)-free combinations of antiretrovirals each worked well as a first-line treatment for HIV, although there were dif...
The FDA has approved Gilead Sciences’ integrase strand transfer inhibitor Vitekta (elvitegravir) for treatment-experienced HIV-positive...
The FDA has approved Triumeq, ViiV Healthcare’s single-tablet, triple-combination antiretroviral regimen, as a first-line therapy to treat..
Tivicay (dolutegravir) suppresses HIV at high rates even among treatment-experienced people with resistance to NRTIs.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.